Journal
BRAIN SCIENCES
Volume 12, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/brainsci12101283
Keywords
breast cancer; cancer-related cognitive impairment; chemotherapy; blood-oxygen-level-dependent (BOLD) signal variability; resting-state fMRI
Categories
Funding
- National Institutes of Health/National Institute on Aging [R01 CA172119, U54 CA137788, P30 CA008748, K24 AG055693-01]
- City of Hope Center for Cancer and Aging
Ask authors/readers for more resources
This study aimed to investigate the impact of chemotherapy on brain functional resting-state signal variability and cognitive function in older long-term survivors of breast cancer. The findings revealed a significant decrease in SDBOLD in the CH group, indicating potential alterations in brain function in breast cancer survivors exposed to chemotherapy.
The purpose of this study was to assess the effect of chemotherapy on brain functional resting-state signal variability and cognitive function in older long-term survivors of breast cancer. This prospective longitudinal study enrolled women age >= 65 years of age who were breast cancer survivors after exposure to chemotherapy (CH), age-matched survivors not exposed to chemotherapy, and healthy controls. Participants completed resting-state functional brain MRI and neurocognitive testing upon enrollment (timepoint 1, TP1) and again two years later (timepoint 2, TP2). There were 20 participants in each of the three groups at TP1. The CH group showed a significant decrease in SDBOLD (blood-oxygen-level-dependent signal variability in standard deviation) in the right middle occipital gyrus (Delta SDBOLD = -0.0018, p = 0.0085, q (p(FDR)) = 0.043 at MNI (42, -76, 17)) and right middle temporal gyrus (Delta SDBOLD = -0.0021, p = 0.0006, q (p(FDR)) = 0.001 at MNI (63, -39, -12)). There were negative correlations between the crystallized composite scores and SDBOLD values at the right inferior occipital gyrus (correlation coefficient r = -0.84, p = 0.001, q (p(FDR)) = 0.016) and right middle temporal gyrus (r = -0.88, p = 0.000, q (p(FDR)) = 0.017) for the CH group at TP1. SDBOLD could be a potentially useful neuroimaging marker for older long-term survivors of breast cancer with exposure to chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available